Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (greater than or equal to 200 mg/dL and less than 500 mg/dL) Despite Statin Therapy.

Trial Profile

Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (greater than or equal to 200 mg/dL and less than 500 mg/dL) Despite Statin Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Dyslipidaemias; Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ANCHOR
  • Sponsors Amarin Corporation
  • Most Recent Events

    • 12 Apr 2018 Results published in an Amarin Corporation Media Release
    • 12 Apr 2018 According to an Amarin Corporation media release, data from this trial presented at the National Kidney Foundation 2018 Spring Clinical Meetings.
    • 12 Mar 2018 According to an Amarin Corporation media release, post-hoc sub-analysis data were presented at the American College of Cardiology 67th Annual Scientific Session and Expo.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top